Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding trial of tolvaptan in chronic renal failure patients on hemodialysis or hemodiafiltration
jRCT2080222101Phase 2
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tolvaptan in chronic kidney disease (CKD) and end-stage kidney disease (ESKD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Efficacy of tolvaptan in chronic renal failure patients on hemodialysis or hemodiafiltration.
02
Drugs
tolvaptan
03
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2080222101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222101.